Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Flushing Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines

NCT05029596
View directory record Official record
Conditions
Cancer
Interventions
Normal Saline Group, Heparin Group
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

NCT00160342
View directory record Official record
Conditions
Hot Flushes, Menopause, Postmenopause
Interventions
Esterified Estrogens (EE) and Methyltestosterone (MT)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
88
States / cities
Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Hot Flushes
Interventions
soy protein, isoflavones, Tamoxifen, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
14
States / cities
Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children

NCT02435069
View directory record Official record
Conditions
Fecal Incontinence, Neurogenic Bowel
Interventions
Dose Response - NS and USP Glycerin - First Intervention, Effectiveness - NS and USP Glycerin - Second Intervention
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 10, 2026, 9:59 AM EDT
Active, not recruiting Not applicable Interventional

Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12

NCT05454189
View directory record Official record
Conditions
Maintenance of Implanted Port Devices
Interventions
Reduced IPD Flush Schedule, Standard IPD Flush Schedule
Device
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
17
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Dr. Tagliaferri's Menopause Formula

NCT01957306
View directory record Official record
Conditions
Hot Flashes
Interventions
Dr. Tagliaferri's Menopause Formula
Dietary Supplement
Lead sponsor
Herba Buena, Inc
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jun 10, 2026, 9:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Prostaglandins on Niacin-Induced Flushing

NCT00930839
View directory record Official record
Conditions
Flushing
Interventions
Niacin and aspirin
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Jun 10, 2026, 9:59 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

ALDH2 Genetic Testing in East Asian Community

NCT07392775
View directory record Official record
Conditions
Healthy Adult, Flushing
Interventions
Genetic Test Results Return, Alcohol Flushing Education
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Terminated No phase listed Observational Results available

Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters

NCT01586026
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Quincy, Illinois • Shreveport, Louisiana • Chesterfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes

NCT00992914
View directory record Official record
Conditions
Hot Flashes, Menopause
Interventions
Sympathetic nerve block with 1% lidocaine 1-2 ml, Superficial subcutaneous injection
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jun 10, 2026, 9:59 AM EDT
Not yet recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea

NCT07600424
View directory record Official record
Conditions
Rosacea, Rosacea, Erythematotelangiectatic, Flushing
Interventions
Transaricular vagus nerve stimulation (taVNS)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Treatment of Facial Flushing With Botulinum Toxin A Injections

NCT02216838
View directory record Official record
Conditions
Facial Flushing
Interventions
botulinum toxin A, Saline Control
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-rebreather at Flush Rate Compared to Bag Valve Mask With Assist

NCT02841592
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Flush rate oxygen, Flush rate oxygen with assist
Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

NCT00683800
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

NCT07408115
View directory record Official record
Conditions
Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats, Hot Flushes, Night Sweats, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms Associated With Menopause
Interventions
JDS-HF3.0
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Jun 10, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement

NCT07453693
View directory record Official record
Conditions
UTI's
Interventions
FLUSH
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

NCT03122301
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block injection with bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jun 10, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT06957691
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions
fezolinetant - reference formulation, Placebo
Drug
Lead sponsor
Shehzad Basaria, M.D.
Other
Eligibility
40 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)

NCT00913081
View directory record Official record
Conditions
Flushing
Interventions
Quercetin, Placebo
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Lanreotide, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jun 10, 2026, 9:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Hot Water Therapy for the Treatment of Menopause-related Hot Flashes

NCT06192329
View directory record Official record
Conditions
Menopause, Menopause Related Conditions, Menopause Syndrome
Interventions
Hot water therapy, Warm water immersion
Behavioral
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 10, 2026, 9:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Menopausal Treatment Using Relaxation Exercises (MaTURE)

NCT01466998
View directory record Official record
Conditions
Hot Flushes, Hot Flashes
Interventions
Paced Respiration, Music Therapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jun 10, 2026, 9:59 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Study of MF101 in Postmenopausal Women

NCT00906308
View directory record Official record
Conditions
Hot Flushes, Vasomotor Symptoms
Interventions
MF101 5 g/day, Placebo, MF101 10 g/day
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Jun 10, 2026, 9:59 AM EDT